Luye Pharma Group, Ltd.
http://www.luye.cn/lvye_en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Luye Pharma Group, Ltd.
Strong Sales, Deals Propel China Biotechs To 2023 Profitability
Strong sales growth and licensing activity in 2023 helped multiple Chinese biotechs to a solid profit performance, some moving into the black for the first time.
Enzene CEO On Biosimilar Denosumab And Cetuximab; Medicare Negotiation Impact On US Market
CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.
Boan Biotech Begins International Phase III Trial Of Denosumab Biosimilars
Having already launched one of its denosumab biosimilar products in China, Boan Biotech has now commenced an international Phase III study to secure approval in Europe, the US and Japan.
With Prolia Rival In The Bag, China’s Luye Takes Aim At Xgeva Biosimilar
Boan Biotech is continuing its ascent in Chinese biosimilars by filing another product with the country’s regulator.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Beijing WBL Peking University Biotech Co., Ltd
- Nanjing Luye Sike Pharma Co., Ltd
- Shandong Luye Pharmaceutical Co., Ltd
- Sichuan Luye Baoguang Pharmaceutical Industry Co., Ltd
- Shandong Boan Biological Technology Co. Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice